novo nordisk glp-1 receptor agonist medications Oral Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients Researchers reveal benefits, risks linked

Future studies whenever feasible might continue to explore heterogeneity of treatment effects of GLP1 receptor agonists or SGLT2 inhibitors, especially in clinically relevant subgroups, across BMI strata, and across age strata, which may suggest opportunities to optimize personalized dementia risk mitigation based on risk profiles

[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Nauck M, Stockmann F, Ebert R & Creutzfeldt W Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

March 8, 2024

In addition, recent studies indicate that some GLP1R agonists, such as liraglutide, semaglutide, and dulaglutide, exert cardiovascular and renal benefits, and are endorsed for use in patients with these complications

Of the included studies, five were RCTs [20,21,22,23,24] and five were cohort studies [25,26,27,28,29]

First-line therapies include weight loss interventions and the carbonic anhydrase inhibitors such as acetazolamide, which reduce CSF production